Just as it did with blood pressure drugs containing valsartan and ranitidine heartburn drugs, the recall of certain extended-release diabetes drugs due to unacceptable levels of N-nitrosodimethylamine (NDMA) is expanding. The FDA reported Tuesday that Amneal Pharmaceuticals Inc., of Bridgewater, N.J., is recalling all lots of metformin hydrochloride extended-release tablets, 500 mg and 750 mg, after seven lots tested by the FDA exceeded the allowable level of NDMA, a probable human carcinogen. The news comes a day after Apotex Corp., part of Toronto-based Apotex Inc., recalled all lots of its 500-mg metformin hydrochloride extended-release tablets for the same reason. Amneal’s immediate-release tablets are not affected by the recall.

No Comments